Article

The role of integrin alpha(D)beta(2) (CD11d/CD18) in monocyte/macrophage migration

Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Experimental Cell Research (Impact Factor: 3.37). 07/2008; 314(14):2569-78. DOI: 10.1016/j.yexcr.2008.05.016
Source: PubMed

ABSTRACT Integrin alpha(D)beta(2) (CD11d/CD18) is a multiligand macrophage receptor with recognition specificity identical to that of the major myeloid cell-specific integrin alpha(M)beta(2) (CD11b/CD18, Mac-1). Despite its prominent upregulation on inflammatory macrophages, the role of alpha(D)beta(2) in monocyte and macrophage migration is unknown. In this study, we have generated model and natural cell lines expressing different densities of alpha(D)beta(2) and examined their migration to various extracellular matrix proteins. When expressed at a low density, alpha(D)beta(2) on the surface of recombinant HEK293 cells and murine IC-21 macrophages cooperates with beta(1)/beta(3) integrins to support cell migration. However, its increased expression on the alpha(D)beta(2)-expressing HEK293 cells and its upregulation by PMA on the IC-21 macrophages result in increased cell adhesiveness and inhibition of cell migration. Furthermore, ligation of alpha(D)beta(2) with anti-alpha(D) blocking antibodies restores beta(1)/beta(3)-driven cell migration by removing the excess alpha(D)beta(2)-mediated adhesive bonds. Consistent with in vitro data, increased numbers of inflammatory macrophages were recovered from the inflamed peritoneum of mice after the administration of anti-alpha(D) antibody. These results demonstrate that the density of alpha(D)beta(2) is critically involved in modulating macrophage adhesiveness and their migration, and suggest that low levels of alpha(D)beta(2) contribute to monocyte migration while alpha(D)beta(2) upregulation on differentiated macrophages may facilitate their retention at sites of inflammation.

0 Followers
 · 
176 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Proteolytic enzymes, such as matrix metalloproteinases (MMP), are associated to the progression of several cancers. They degrade extracellular components, which helps tumors to expand and cancer cells to escape from the primary site. Of all MMPs, gelatinases (MMP-2 and -9) and membrane type-1 matrix metalloproteinase (MT1-MMP, MMP-14), in particular, are often associated to more aggressive types of head and neck carcinomas as well as to a poorer outcome in patient survival. Although therapies during the last decades have advanced, the mortality of the disease is still rather high and adjuvant therapies are searched for continuously. MMP-9 and MT1-MMP are also involved in neo-angiogenesis, which is necessary for tumor expansion. For this reason, we have identified synthetic peptides-targeting gelatinases and MT1-MMP, and have also evaluated their anticancer effects in vitro and in vivo. Antigelatinolytic peptides effectively inhibited tongue-carcinoma cell invasion and reduced the growth of xenografted tumors. In tumor samples of mice that were treated with antigelatinolytic peptides, the micro-vessel density was significantly reduced. We also identified a novel MT1-MMP targeting peptide and demonstrated that it exerted anticancer effects against several malignant cell lines in vitro. The effects of MT1-MMP inhibition on tongue-squamous cell carcinomas were evaluated by using xenograft tumors, which it effectively inhibited. Tranexamic acid was also demonstrated to inhibit tongue-squamous cell carcinoma invasion, most probably due to its ability to prevent the plasmin-mediated activation of proMMP-9. Leukocyte β2 integrins are another interesting option when evaluating targets for the therapeutic intervention of inflammatory conditions or malignancies of hematopoietic origin, since β2 integrins are expressed mainly by leukocytes. We identified a novel technique for screening small-molecule libraries against β2 integrins, and by using this technique we identified a novel αMβ2 integrin-binding chemical (IMB-10). IMB-10 significantly enhances leukocyte adhesion and inhibits their motility. We also demonstrated that IMB-10 can be used to inhibit inflammation and lymphoma growth in vivo. Interestingly, IMB-10 also reduced leukocyte tumor infiltration and inhibited tumor invasion. Syövän paikallisessa leviämisessä ja etäpesäkkeiden muodostumisessa on erilaisilla proteiineja sekä muita solunulkoisia rakenneosia tuhoavilla entsyymeillä keskeinen rooli. Matriksin metalloproteinaasit (MMP) ovat ryhmä ehkä keskeisimpiä, ja eniten tutkittuja proteiineja hajottavia entsyymejä. MMP:t pystyvät tuhoamaan suurinta osaa solunulkoisentukiverkon ja solujen tyvikalvon rakenneosasista, osallistuvat syöpäkasvainten verisuonien uudismuodostukseen, sekä kykenevät aktivoimaan ja inaktivoimaan suurta joukkoa elimistön viestimolekyylejä. Etenkin MMP-2, -9 ja -14 on osoitettu vahvasti liittyvän pään ja kaulanalueensyöpien kasvuun sekä taudin ennusteeseen. Tästä syystä olemme kehittäneet 10-12 aminohapon ketjuja, peptidejä, jotka pystyvät estämään näitä entsyymejä. Osoitimme että nämä peptidit pystyivät estämään useiden eri syöpäsolujen liikettä solumaljalla, estivät hiiriin siirrettyjen ihmisen kielisyöpäsolujen kykyä muodostaa kasvaimia, sekä osin vähensivät näiden kasvainten verisuonenmuodostusta. Tulokset ovat lupaavia, ja peptidit saattavat tarjota tulevaisuudessa yhden mahdollisuuden parantaa suusyöpäpotilaiden ennustetta, jos kasvainten entsyymiprofiileihin kyetään keskittymään yksilöllisesti. Toinen tutkimuslinjamme oli kehittää menetelmä jolla löytää aineita jotka kykenevät estämään valkosolujen pinnalla esiintyviä tartunta- ja liikuntarakenteita, integriinejä. Valkosoluille tyypillisten beta-2-integriinien esto on mielenkiintoinen tutkimuskohde etenkin tulehduksellisissa sairauksissa ja verisyövissä, mutta tulehdusreaktion on osoitettu liittyvän olennaisesti myös kiinteinten syöpäkasvainten kasvuun. Osoitimme että kehittämällämme menetelmällä voidaan löytää kymmeniätuhansia keinotekoisia molekyylejä sisältävistä molekyylikirjastoista alfa-M-beta-2 -integriinejä estävä pienmolekyyli. Osoitimme myös että tämä uusi molekyyli pystyy estämään verisyöpäsolujen tarttumista soluviljelmissä, estämään kokeellista vatsakalvontulehdusta hiirimallissa, sekä estämään hiireen siirrettyjen ihmisen verisyöpäsolujen jakautumista ja kasvua. Mielenkiintoista oli että molekyyli esti jossain märin myös kielisyöpäkasvainten kasvua ja kudostuhoa hiiressä, vaikka kyseiset solut eivät tuota beta-2 integriinejä. Tämä osoittaa että tulehduksella voi olla merkitystä myös kielisyövän ennusteeseen. Löydetty pienmolekyyli on mielenkiintoinen kandidaatti etenkin tulehduksellisiin sairauksien sekä verisyöpien tulevaisuuden lääketutkimuksiin.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A mAb targeting the CD11d subunit of the leukocyte integrin CD11d/CD18 decreases intraspinal inflammation and oxidative damage leading to improved neurological outcomes in rodent models of SCI. CD11d/CD18 is the fourth member of the beta2-integrin family. Current evidence indicates that CD11d/CD18 is regulated differently than other beta2-integrins, suggesting that CD11d(+) leukocytes play a distinct role in inflammation. Although the transcriptional control of CD11d expression has been evaluated, control of the intracellular distribution of CD11d has not been addressed. For this reason and as a result of the potential of CD11d as a therapeutic target for SCI and possibly other CNS injuries, we investigated the intracellular localization and surface expression of CD11d in cultured cells. CD11d and CD18 were fused at their C-termini with YFP and mRFP, respectively. Flow cytometry and confocal microscopy demonstrated that rCD11d-YFP is expressed on the cell surface of leukocyte cell lines expressing CD18. In contrast, in heterologous cell lines, CD11d-YFP is retained intracellularly in the TGN. Coexpression of CD11d-YFP and CD18-mRFP relieves this intracellular restriction and allows the CD11d/CD18 heterodimer to be surface-expressed. Based on domain-swapping experiments with CD25, the extracellular domain of CD11d is required and sufficient for the observed intracellular retention in heterologous cells. Furthermore, the transmembrane and C-terminus are also required for proper heterodimerization with CD18 and localization to the plasma membrane. These findings suggest that multiple CD11d domains play a role in controlling intracellular location and association with CD18.
    Journal of leukocyte biology 08/2009; 86(4):851-62. DOI:10.1189/jlb.0309150 · 4.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Integrins are heterodimeric receptors composed of alpha and beta transmembrane subunits that mediate attachment of cells to the extracellular matrix and counter-ligands such as ICAM-1 on adjacent cells. beta2 integrin (CD18) associates with four different alpha (CD11) subunits to form an integrin subfamily, which has been reported to be expressed exclusively on leukocytes. However, recent studies indicate that beta2 integrin is also expressed by other types of cells. Since the gene for beta2 integrin is located in the region of human chromosome 21 associated with congenital heart defects, we postulated that it may be expressed in the developing heart. Here, we show the results from several different techniques used to test this hypothesis. PCR analyses indicated that beta2 integrin and the alphaL, alphaM, and alphaX subunits are expressed during heart development. Immunohistochemical studies in both embryonic mouse and chicken hearts, using antibodies directed against the N- or C-terminal of beta2 integrin or against its alpha subunit partners, showed that beta2 integrin, as well as the alphaL, alphaM, and alphaX subunits, are expressed by the endothelial and mesenchymal cells of the atrioventricular canal and in the epicardium and myocardium during cardiogenesis. In situ hybridization studies further confirmed the presence of beta2 integrin in these various locations in the embryonic heart. These results indicate that the beta2 integrin subfamily may have other activities in addition to leukocyte adhesion, such as modulating the migration and differentiation of cells during the morphogenesis of the cardiac valves and myocardial walls of the heart.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 01/2010; 43(1):25-35. DOI:10.1590/S0100-879X2010000100005 · 1.08 Impact Factor

Preview

Download
2 Downloads
Available from